| Date Filed | Type | Description |
| 09/29/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/22/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...|
Docs:
|
"PRE-FUNDED WARRANT THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY APPLICABLE STATE SECURITIES LAWS. WITHOUT SUCH REGISTRATION, SUCH SECURITIES MAY NOT BE SOLD OR OTHERWISE TRANSFERRED AT ANY TIME WHATSOEVER UNLESS IN THE OPINION OF COUNSEL SATISFACTORY TO THE COMPANY REGISTRATION IS NOT REQUIRED FOR SUCH TRANSFER AND THAT SUCH TRANSFER WILL NOT BE IN VIOLATION OF THE APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR ANY RULE OR REGULATION PROMULGATED THEREUNDER.. IMMIX BIOPHARMA, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. Number of Shares: Origina...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is entered into as of August 21, 2023 , by and between Immix Biopharma, Inc., a Delaware corporation , and the subscriber identified on the signature pages hereto . WHEREAS: The Company desires to issue and sell to the Subscriber such number of shares of the Company’ s common stock, par value $0.0001 per share and such number of pre-funded warrants in the form attached hereto as to purchase such number of shares of Common Stock as set forth on the signature page to this Agreement. NOW, THEREFORE, for and in consideration of the premises and the mutual covenants hereinafter set forth, the parties hereto do hereby agree as follows: SUBSCRIPTION 1.1 Subject to the terms and conditions hereinafter set forth, the Subscriber hereby..." |
|
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/14/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/14/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/22/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
8-K/A
| Regulation FD Disclosure Interactive Data |
| 01/18/2023 |
8-K
| Quarterly results |
| 01/12/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/03/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 12/16/2022 |
8-K
| Investor presentation |
| 12/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/18/2022 |
RW
| Form RW - Registration Withdrawal Request: |
| 06/30/2022 |
RW WD
| Form RW WD - Withdrawal of Registration Withdrawal Request: |
| 06/09/2022 |
8-K
| Quarterly results |
| 05/27/2022 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 05/27/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 05/13/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/25/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/28/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/02/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2022 |
SC 13G/A
| Altium Capital Management LP reports a 1.6% stake in Immix Biopharma, Inc. |
| 02/09/2022 |
SC 13G
| Murchinson Ltd. reports a 5.3% stake in Immix Biopharma, Inc. |
| 01/25/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
|